Ownership Summary
Northwest Biotherapeutics Inc (OTC:NWBO) currently has 6 active institutional owners and shareholders as of today (September 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).
- The percentage of Northwest Biotherapeutics owned by institutions changed from 0.0% in June 2025 to 0.0% in September 2025, marking a slight down trend.
- On a quarter-over-quarter basis, institutional holdings shifted by -11.67%, with a year-over-year a decrease of 25.00% in the count of filers.
- The latest 13F cycle for Northwest Biotherapeutics reveals that of 6 total investors, 0 funds grew their exposure, whereas 1 reduced theirs and 5 made no changes.
- The aggregate institutional position in Northwest Biotherapeutics now stands at 179.32K shares as of September 2025, after investors decreased their holdings (down by 23.70K shares quarter on quarter which is up 14.95K shares year over year).
- VSM Wealth Advisory, LLC's holding of 65.57K shares as of September 30, 2025 makes it the primary institutional investor in Northwest Biotherapeutics, owning 0.00% of the stock.
- Leading sellers of Northwest Biotherapeutics stock in September 2025 included Ethos Financial Group, LLC (23.70K).
- The top 6 institutional holders of Northwest Biotherapeutics for the quarter ending September 2025 included VSM Wealth Advisory, LLC (65.57K), Opus Capital Group, LLC (60.15K), Williams Jones Wealth Management, LLC. (27.00K), Ethos Financial Group, LLC (25.35K), Coston, McIsaac & Partners (1.00K), HANTZ FINANCIAL SERVICES, INC. (250).